BPC August 27 update

​Prothena PRTA +26% on ownership stake by EcoR1 Capital; Sophiris SPHS offering -15%

Price and Volume Movers

Prothena Corporation plc (NASDAQ:PRTA) shares closed up 26% to $8.93, following the filing of a Schedule 13D by EcoR1 Capital on Monday, where it reported a $23.6% ownership stake of the company.

Sophiris Bio Inc. (Nasdaq: SPHS) announced a registered direct offering with one institutional investor for the sale of 5,333,334 shares (or pre-funded warrants to purchase common shares) for an effective price of $0.75 per share, for gross proceeds of approximately $4m. Shares closed down 15% to $0.81.

Mallinckrodt Pharmaceuticals (NYSE: MNK) shares closed down 16% to $3.56 on news that the U.S. Court of Appeals for the Federal Circuit upheld a Federal District Court’s decision rejecting Mallinckrodt’s patent infringement lawsuit against Praxair, Inc.’s nitric oxide drug product delivery system.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume


Plus Therapeutics, Inc. (PSTV): $14.95; +44%.

Cidara Therapeutics, Inc. (CDTX): $1.50; +11%.

Avadel Pharmaceuticals plc (AVDL): $2.45; +9%.

Diffusion Pharmaceuticals Inc. (DFFN): $2.24; +9%.

OncoSec Medical Incorporated (ONCS): $2.04; +8%.


Liquidia Technologies Inc.( LQDA): $4.55; -18%.

Endo International plc (ENDP): $2.55; -12%.

Celldex Therapeutics, Inc. (CLDX): $2.07; -11%.

Odonate Therapeutics, Inc. (ODT): $30.32; -11%.

Cerecor Inc. (CERC): $2.99; -10%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ARVN – Arvinas Inc.
ER+ positive / HER2- negative breast cancer

Phase 1 Phase 1 initial data presented October 23, 2019. Further data due 2H 2020.
$1.8 billion

DMPI – DelMar Pharmaceuticals Inc.
MGMT-unmethylated newly diagnosed Glioblastoma Multiforme (GBM)

Phase 2 Phase 2 further data due at AACR April 24 - 29, 2020. Top-line data due August 2020.
$5.5 million

DMPI – DelMar Pharmaceuticals Inc.
MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Phase 2 Phase 2 further data due at AACR April 24-29, 2020.
$5.5 million

Wet age-related macular degeneration (wet AMD)

Phase 1/2 Phase 1/2 one-year data from Cohorts 4 and 5 are expected in mid-2020. Two-year data from Cohorts 1-3 due 1Q 2020.
$1.5 billion